Roche Venture pushes Curetis Series A to $48M; GlobeImmune inks hep B pact with Gilead; Poxel touts diabetes data;

 @FierceBiotech: Special Report: Top 15 blockbuster contenders in the biopharma pipeline. Report | Follow @FierceBiotech

 @JohnCFierce: Last Feb. Conatus raised $20M from VCs, including Roche, largely on the promise of 1027.| Follow@JohnCFierce

>  Germany's Curetis says it has raised $13 million to back the development of its diagnostic tests. Forbion and Roche Venture Fund led the expansion of the Series A, which now totals $48 million. Report

> GlobeImmune has won an unspecified upfront and additional support from Gilead in a new pact to develop a hep B treatment which uses Gilead's Viread. Story

> France's Poxel says its experimental type 2 diabetes drug achieved its primary endpoint in a Phase II study, providing some confidence that it can go on to become a second-line treatment. Release

> Bainbridge Island, WA-based Emerald BioStructures announced a three-year extension of its collaboration with UCB, providing research funding, milestones and royalties on future drug product revenues. Release

Pharma News

Mylan puts Bresch into CEO chair. Item

> Novartis eye unit subpoenaed in U.S. probe. Article

> GSK sales grow, thanks to emerging markets, Japan. Story

> CDC group backs Gardasil for routine use in males. Report

Drug Delivery

> MonoSol targets drug film rival's revenue in updated court complaint. Item

> Shire pump bypasses hurdle to sneak enzyme drug into brain. Story

> DLVR Therapeutics grabs $2M in seed support, advancing nanoparticle delivery. Article

Medical Device News

> Quest begins search for CEO. Article

> FDA raises concerns about Medtronic heart device. News

> Foundation Medicine to collaborate with J&J unit. Story

And Finally... A decision by the government of Victoria in Australia to provide a $55 million support program for biotech has spurred debate over the potential rewards. Column